A 40-year-old Colombian female patient, allergic to non-steroidal anti-inflammatory drugs and with no other relevant medical history, attended the emergency department at a tertiary care hospital of Barcelona, Spain in 2020, due to a 4-day mucocutaneous eruption without associated fever. She had presented with a similar self-resolving symptoms two years prior, which was diagnosed as chickenpox. She did not take any medication and denied having had a herpes outbreak or had any other infections in the previous few weeks.

On examination, she presented with multiple targetoid erythematous-violaceous circular plaques on the thorax, arms and back of the hands, some with a central vesicle [Figure 1]. The oro-genital mucosa showed painful haemorrhagic crusts and erosions [Figure 2].

Erythema multiforme (EM) was suspected clinically. A skin biopsy was performed and treatment was started with a tapered dosage of prednisone, topical methylprednisolone (1 mg/g) and ebastine (10 mg/12 hours). The biopsy showed vacuolar degeneration of the basal layer of the epidermis and spongiosis with isolated colloid bodies corresponding to an interface dermatitis. Direct immunofluorescence showed fibrinogen deposits within the basement membrane and immunoglobulin (Ig)G, IgA, IgM and fraction C3 within the intraepidermal colloid bodies. Both results supported the diagnosis of EM. After two weeks, the lesions resolved, leaving residual hyperpigmentation.

The patient in this manuscript has given written informed consent for publication purposes of their case details.

Comment

EM is a sudden-onset hypersensitivity reaction which usually resolves within 2–4 weeks. It usually manifests in young individuals with target-like concentric erythematous-bullous skin lesions, predominantly affecting acral and facial areas. These lesions typically measure less than 3 cm in diameter, have a regular
round shape with a central dusky zone and two concentric outer rings. EM targetoid lesions are often palpable and should be distinguished from the atypical ‘targets’ that can be seen in Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), which are round, asymmetric, non-palpable lesions with only two zones and a poorly defined border.¹

The EM spectrum has been classified into major and minor forms, the latter associated with mild or absent mucosal affection and acral location of the skin lesions. Severe mucosal involvement is characteristic of major EM and usually consists in vesiculobullous lesions which rapidly develop into painful erosions that can give rise to serohaemorrhagic crusts. General symptoms such as fever, asthenia and arthralgias usually precede and accompany the skin lesions.

Infections trigger a significant percentage of cases, the most common being herpes simplex virus and Mycoplasma pneumoniae. The administration of drugs such as sulfonamides, non-steroidal anti-inflammatory drugs and penicillines, account for less than 10% of cases.²

EM requires differentiation from SJS/TEN as these conditions can be life threatening. Many other conditions can display targetoid vesiculobullous lesions or mucosal involvement and could be mistaken for EM, including urticaria, fixed drug eruptions, bullous pemphigoid, paraneoplastic pemphigus or Rowell syndrome.³ A skin biopsy could be helpful to distinguish these entities from EM. Possible findings on direct immunofluorescence include granular deposition of C3 and IgM at the dermo-epidermal junction. However, direct immunofluorescence is usually non-specific in EM and its purpose is to exclude other similar conditions.⁴

Mild disease can be managed in most patients with topical steroids, analgesic agents and anti-histamines. When identified, treatment of any underlying infection should be instituted. Patients with severe EM may require systemic steroids.⁴

It is important to differentiate EM from other erythematous-bullous pathologies, with typical target-like lesions, a key diagnostic clue.⁵

AUTHORS’ CONTRIBUTION

FA-R conceptualised and designed the work and drafted the manuscript. NC performed the histopathological analysis and interpretation. XB-A collected the data. NC and XB-A critically revised the manuscript. All authors approved the final version of the manuscript.

References

1. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol 2013; 69:173.e1–13. https://doi.org/10.1016/j.jaad.2013.05.003.

2. Samim F, Auluck A, Zed C, Williams PM. Erythema multiforme: A review of epidemiology, pathogenesis, clinical features, and treatment. Dent Clin North Am 2013; 57:583–96. https://doi.org/10.1016/j.cden.2013.07.001.

3. Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: A review for the practicing dermatologist. Int J Dermatol 2012; 51:889–902. https://doi.org/10.1111/j.1365-4632.2011.05348.x.

4. Trayes KP, Love G, Studdiford JS. Erythema Multiforme: Recognition and management. Am Fam Physician 2019; 100:82–8.

5. Rizo-Potau D, Marti-Marti I, Fustà-Novell X. Erythema multiforme. Med Clin (Barc) 2021; 156:533. https://doi.org/10.1016/j.medcli.2020.04.063.